RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Nature

Volumn 468, Issue 7320, 2010, Pages 103-107

  Gonzalez Suarez, Eva ^a,c   Jacob, Allison P ^a   Jones, Jon ^a   Miller, Robert ^a   Roudier Meyer, Martine P ^a   Erwert, Ryan ^a   Pinkas, Jan ^b,d   Branstetter, Dan ^a   Dougall, William C ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GESTAGEN; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

APOPTOSIS; CYTOLOGY; HORMONE; INHIBITION; PREGNANCY; RODENT; SEXUAL MATURITY; TUMOR; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CELL PROLIFERATION; CONTROLLED STUDY; LOSS OF FUNCTION MUTATION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MULTIPARA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MEDROXYPROGESTERONE ACETATE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; PROGESTERONE; PROGESTINS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

EID: 78149284767     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09495     Document Type: Article

References (28)

1. Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
2. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
3. Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 (2000).
4. Beleut, M. et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl Acad. Sci. USA 107, 2989-2994 (2010).
5. Fernandez-Valdivia, R. et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol. 328, 127-139 (2009).
6. Gonzalez-Suarez, E. et al. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell. Biol. 27, 1442-1454 (2007).
7. Aldaz, C. M., Liao, Q. Y., LaBate, M. & Johnston, D. A. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 17, 2069-2072 (1996).
8. Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P. & Hinds, P. W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9, 13-22 (2006).
9. Wang, T. C. et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669-671 (1994).
10. Cao, Y. et al. IKKa provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763-775 (2001).
11. Guy, C. T. et al. Expression of the neuprotooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl Acad. Sci. USA 89, 10578-10582 (1992).
12. Luo, J. L. et al. Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin. Nature 446, 690-694 (2007).
13. Herschkowitz, J. I. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76 (2007).
14. Hewitt, S. C. et al. Lackofductal development inthe absenceof functional estrogen receptoradelays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res. 62, 2798-2805 (2002).
15. Joshi, P. A. et al. Progesterone induces ad ult mammary stem cell expansion. Nature 465, 803-807 (2010).
16. Klijn, J. G., Setyono-Han, B. & Foekens, J. A. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65, 825-830 (2000).
17. Ismail, P. M. et al. Progesterone involvement in breast development and tumorigenesis-as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 68, 779-787 (2003).
18. Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798-802 (2010).
19. Aupperlee, M., Kariagina, A., Osuch, J. &Haslam, S. Z. Progestins and breast cancer. Breast Dis. 24, 37-57 (2005).
20. Hofseth, L. J. et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84, 4559-4565 (1999).
21. Greendale, G. A. et al. Postmenopausal hormone therapy and change in mammographic density. J. Natl Cancer Inst. 95, 30-37 (2003).
22. Chlebowski, R. T. et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women:theWomen'sHealth Initiative Randomized Trial. J. Am. Med. Assoc. 289, 3243-3253 (2003).
23. Holmberg, L. et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475-482 (2008).
24. Van Poznak, C. et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kB ligand (RANKL) in human breast tumours. J. Clin. Pathol. 59, 56-63 (2006).
25. Brisken, C. et al. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc. Natl Acad. Sci. USA 95, 5076-5081 (1998).
26. Cardiff, R. D. et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19, 968-988 (2000).
27. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
28. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).